CART-EGFR
/ Chinese PLA General Hospital, AbelZeta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 29, 2015
Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
(clinicaltrials.gov)
- P1/2; N=60; Recruiting; Sponsor: Chinese PLA General Hospital; N=10 ➔ 60
Enrollment change • Biosimilar • Colorectal Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma
January 30, 2016
Cellular Biomedicine: Biotech Showcase 2016
(Cellular Biomedicine Group)
- Anticipated initiation of P1/2b trials in multiple indications in China in H1 2016; Anticipated initiation of multicenter trial in cholangiocarcinoma and other indications in 2016
Anticipated new P1/2 trial • Anticipated new trial • Oncology
November 05, 2015
Cellular Biomedicine: World Congress on Cancer Therapy 2015
(Cellular Biomedicine Group)
- “The EGFR-targeting CART cell therapy for EGFR-positive, advanced, relapsed/refractory solid tumor patients is safe, well tolerated and shows positive signal of clinical activity”
P1/2 data • Oncology
November 05, 2015
Cellular Biomedicine: ECC 2015
(Cellular Biomedicine Group)
- “Adoptive CART immune cell transfer protocol targeting Her-1 is safe, feasible and effective for Her-1 positive advanced relapsed/refractory NSCLC patients”
P1 data • Non Small Cell Lung Cancer • Oncology
August 30, 2015
Cellular Biomedicine: Q2 & H1 2015 Results
(Cellular Biomedicine Group)
- Anticipated P1 data of CAR-T EGFR-HER1-positive advanced lung cancer by September 2016
Anticipated P1 data • Non Small Cell Lung Cancer • Oncology
November 16, 2017
Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients with EGFR-positive Advanced Biliary Tract Cancers.
(PubMed, Clin Cancer Res)
- P1/2; "The CART-EGFR cell immunotherapy was a safe and active strategy for EGFR-positive advanced BTCs. The enrichment of Tcm in the infused CART-EGFR cells could predict clinical response."
Journal
1 to 6
Of
6
Go to page
1